Table 3.

Univariate and Multivariate Cox Regression Analysis of Patients Who Received Adjuvant Chemotherapy.^a

Outcome	Univariate				Multivariate
	RFS		OS		RFS		OS
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
MLKL	0.56 (0.26-1.17)	.12	0.48 (0.27-0.86) 0.01	.01	0.61 (0.28-1.30)	.20	0.54 (0.30-0.97)	.04
TNM stage	3.71 (1.86-7.42)	<.01	2.96 (1.77-4.95)	<.01	3.80 (1.84-7.83)	<.01	2.03 (1.03-4.02)	<.04
LVI	1.05 (1.01-1.09)	<.01	1.05 (1.03-1.09)	<.01	2.15 (0.80-5.83)	.13	1.97 (0.90-4.32)	.09
LNI	2.44 (1.53-3.88)	<.01	2.38 (1.65-3.44)	<.01	2.44 (1.53-3.88)	<.01	0.99 (0.38-2.54)	.03
Grade	2.63 (1.23-5.60)	.01	2.77 (1.54-4.95)	<.01	1.20 (0.56-2.58)	0.42	1.17 (0.53-2.58)	.70
CEA	0.47 (0.22-1.01)	.05	2.08 (1.16-3.76)	.01	0.47 (0.22-1.01)	.05	1.77 (0.82-3.82)	.14

Abbreviations: CEA, carcino embryonie antigen; CI, confidence interval; HR, hazard ratio; MLKL, mixed lineage kinase domain-like protein; LNI, positive lymphatic node invasion; LVI, lymphovascular invasion; OS, overall survival; RFS, recurrence-free survival; TNM, tumor node metastasis.

^an = 79.

^bBold type denotes statistical significance.